Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
23.3 USD | -5.21% | -0.47% | +28.87% |
Financials (USD)
Sales 2024 * | 38.27M | Sales 2025 * | 31.72M | Capitalization | 1.05B |
---|---|---|---|---|---|
Net income 2024 * | -193M | Net income 2025 * | -237M | EV / Sales 2024 * | 19.1 x |
Net cash position 2024 * | 318M | Net cash position 2025 * | 254M | EV / Sales 2025 * | 25.1 x |
P/E ratio 2024 * |
-5.45
x | P/E ratio 2025 * |
-4.81
x | Employees | 284 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 11.44% |
Latest transcript on Bicycle Therapeutics plc
1 day | -5.21% | ||
1 week | -0.47% | ||
Current month | -0.64% | ||
1 month | +1.48% | ||
3 months | +36.02% | ||
6 months | +58.61% | ||
Current year | +28.87% |
Managers | Title | Age | Since |
---|---|---|---|
Kevin Lee
CEO | Chief Executive Officer | 55 | 15-08-31 |
Alethia Young
DFI | Director of Finance/CFO | 45 | 23-07-16 |
Alistair Milnes
COO | Chief Operating Officer | 50 | 20-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Pierre Legault
CHM | Chairman | 63 | 19-03-17 |
Director/Board Member | 61 | 21-03-16 | |
Richard Kender
BRD | Director/Board Member | 68 | 19-07-23 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.06% | 0 M€ | 0.00% | - | |
0.05% | 0 M€ | 0.00% | - | |
0.03% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-06 | 23.3 | -5.21% | 424,084 |
24-05-03 | 24.58 | -0.45% | 324,430 |
24-05-02 | 24.69 | +2.02% | 606,373 |
24-05-01 | 24.2 | +3.20% | 389,430 |
24-04-30 | 23.45 | +0.17% | 270,253 |
Delayed Quote Nasdaq, May 06, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+28.87% | 1.05B | |
+9.15% | 105B | |
-1.08% | 104B | |
+5.79% | 22.94B | |
-11.55% | 22.34B | |
-7.01% | 19.25B | |
-37.08% | 17.08B | |
-9.91% | 16.96B | |
+7.55% | 14.16B | |
+40.04% | 12.63B |
- Stock Market
- Equities
- BCYC Stock